Intranasal corticosteroids potency

AV006 was a multi-center, randomized, double-blind, placebo-controlled trial performed in . children without high-risk medical conditions to evaluate the efficacy of FluMist against culture-confirmed influenza over two successive seasons using the frozen formulation. The primary endpoint of the trial was the prevention of culture-confirmed influenza illness due to antigenically matched wild-type influenza in children, who received two doses of vaccine in the first year and a single revaccination dose in the second year. During the first year of the study 1602 children 15-71 months of age were randomized 2:1 (vaccine:placebo). Approximately 85% of the participants in the first year returned for the second year of the study. In Year 2, children remained in the same treatment group as in year one and received a single dose of FluMist or placebo. See Table 4 for a description of the results.

Intranasal corticosteroids potency

intranasal corticosteroids potency

Media:

intranasal corticosteroids potencyintranasal corticosteroids potencyintranasal corticosteroids potencyintranasal corticosteroids potencyintranasal corticosteroids potency